logo-education
0370 270 6000

already registered?

Please sign in with your existing account details.

need to register?

Register to access exclusive content, sign up to receive our updates and personalise your experience on brownejacobson.com.

Privacy statement - Terms and conditions

Forgotten your password?

Pupil premium use to be analysed

4 July 2013

The DfE has appointed a Pupil Premium tsar to visit schools and share examples of the best use of Pupil Premium (currently £623 per pupil). In addition, the chief inspector of schools, Michael Wilshaw, has announced that Ofsted inspectors will be asked to review the academic achievement of disadvantaged pupils and those attracting Pupil Premium, in particular.

The plans will see schools which perform badly being investigated by outside head teachers with superior track records on helping disadvantaged children and given recommendations for using Pupil Premium funding more effectively.

How Pupil Premium funds are spent by schools is flexible and a matter for their professional judgement. Disadvantage is a very complex issue and, unsurprisingly, is dealt within different ways in schools. Any clear guidelines on what is expected of schools and advice on the proven, most effective ways to help disadvantaged children achieve their potential must be welcomed.

Related opinions

Does the move into Step 4 mean the ending of Covid-19 restrictions within schools?

With the Prime Ministers announcement that he intends for Step 4 to begin on 19 July, this will also bring an end to the restrictions currently in place on education settings.

View blog

Advocacy in Action: Female Genital Mutilation Protection Orders (FGMPO)

The issue of Female Genital Mutilation Protection Orders and the importance of education providers to act promptly.

View blog

Responsibilities towards students identifying as non-binary

Our top tips for supporting transgender and non-binary pupils.

View blog

Schools face scrutiny over Covid-19 vaccinations for children

On 4 June, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of the Pfizer/BioNTech Covid-19 vaccine for 12- to 15-year-olds.

View blog

Mailing list sign up

Select which mailings you would like to receive from us.

Sign up